A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8(+) T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice

SIMPLE SUMMARY: Treatments for castrate (hormone)-resistant prostate cancer (CRPC) remain limited and are not curative. Although the first (and only) FDA-approved vaccine for CRPC (PROVENGE(®), Sipuleucel-T) has been shown to improve the overall survival of patients, it is not curative and its cost...

Descripción completa

Detalles Bibliográficos
Autores principales: Vu, Pauline Le, Vadakekolathu, Jayakumar, Idri, Sarra, Nicholls, Holly, Cavaignac, Manon, Reeder, Stephen, Khan, Masood A., Christensen, Dennis, Pockley, Alan Graham, McArdle, Stéphanie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032647/
https://www.ncbi.nlm.nih.gov/pubmed/35454873
http://dx.doi.org/10.3390/cancers14081970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032647/
https://www.ncbi.nlm.nih.gov/pubmed/35454873
http://dx.doi.org/10.3390/cancers14081970

Ejemplares similares